Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013569

— · cohortMD2

a48b6369-7b97-5899-ae25-00d1c6311098

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.650
  • ANGIOGENESIS+0.460
  • UV_RESPONSE_DN+0.450
  • PROTEIN_SECRETION+0.420
  • TGF_BETA_SIGNALING+0.390
  • KRAS_SIGNALING_UP+0.340
  • ANDROGEN_RESPONSE+0.300
  • COAGULATION+0.300
  • COMPLEMENT+0.230
  • INFLAMMATORY_RESPONSE+0.230

Top 10 suppressed

  • MYC_TARGETS_V2-0.570
  • E2F_TARGETS-0.350
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
  • CHOLESTEROL_HOMEOSTASIS-0.280
  • G2M_CHECKPOINT-0.260
  • P53_PATHWAY-0.230
  • ESTROGEN_RESPONSE_LATE-0.220
  • GLYCOLYSIS-0.220
  • DNA_REPAIR-0.200
  • INTERFERON_ALPHA_RESPONSE-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-BH-A1EO-01A-11R-A137-07
breast-umap@18
—A0.881
2TCGA-AR-A24T-01A-11R-A169-07
breast-umap@18
—A0.880
3TCGA-BH-A0H3-01A-11R-A12P-07
breast-umap@18
—A0.858
4TCGA-55-6642-01A-11R-1858-07
lung-landscapes@6
—cohortA30.839
5a6105a18-de2b-470c-bbb1-8c1188c57e22
melanoma-umap@29
——0.826
6TCGA-44-6774-01A-21R-1858-07
lung-landscapes@6
—cohortA10.824
7SRR9879273
lung-landscapes@6
—cohortMD20.820
8SRR25043620
head-neck@1
——0.816
9TCGA-A8-A08Z-01A-21R-A00Z-07
breast-umap@18
—A0.814
10TCGA-A2-A0T6-01A-11R-A084-07
breast-umap@18
—A0.813

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.650Inavolisib— uncovered
ANGIOGENESIS0.460Remibrutinib— uncovered
UV_RESPONSE_DN0.450Inavolisib— uncovered
PROTEIN_SECRETION0.420Remibrutinib— uncovered
TGF_BETA_SIGNALING0.390Inavolisib— uncovered
KRAS_SIGNALING_UP0.340Inavolisib— uncovered
ANDROGEN_RESPONSE0.300Inavolisib— uncovered
COAGULATION0.300Binimetinib— uncovered
COMPLEMENT0.230Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.230Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.190Idelalisib— uncovered
IL2_STAT5_SIGNALING0.180Idelalisib— uncovered
HEDGEHOG_SIGNALING0.160Inavolisib— uncovered
MYOGENESIS0.140Inavolisib— uncovered
ALLOGRAFT_REJECTION0.120Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.120Inavolisib— uncovered
APICAL_JUNCTION0.100Inavolisib— uncovered
APOPTOSIS0.090Idelalisib— uncovered
HEME_METABOLISM0.080Temsirolimus— uncovered
PANCREAS_BETA_CELLS0.080Cobimetinib— uncovered